David Thurston is Professor of Drug Discovery in the Institute of Pharmaceutical Science at King’s College London. He has a first degree in pharmacy and a PhD in synthetic medicinal chemistry. David is one of the scientific co-founders of Spirogen Ltd (recently acquired by AstraZeneca), and acted as CSO for the company from its formation in 2000 until 2011. He is also a co-founder of Transcriptogen Ltd, which focusses on the discovery and development of small-molecule transcription factor inhibitors as oncology agents, and Femtogenix Ltd which is involved with the discovery of novel DNA Minor Groove Binding Agents (MGBAs) with potential application as ADC payloads. David has published widely in medicinal chemistry/chemistry journals, is author of the textbook “Chemistry and Pharmacology of Anticancer Drugs”, and Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry.

Paul Jackson holds an undergraduate degree in the pharmaceutical sciences (LJMU), an MSc in Bioinformatics (University of Liverpool) and a PhD in Computational Drug Discovery (King’s College London). He has extensive experience in in silico methods, including structure-, ligand- and fragment-based drug design. He has also been involved in the development of QSAR, lead optimization and molecular docking techniques. Both his PhD and post-doctoral research have involved the development of novel computational chemistry methods (e.g., molecular dynamics simulation techniques) for the design and evaluation of ADC payloads, which has contributed to Femtogenix’s novel payload discovery platform, a company of which he is scientific co-founder. Dr Jackson also provided the modelling support for the discovery of the novel NF-κB inhibitor TSG-1301 (KMR-28-39) which is presently in development with Transcriptogen Ltd, a company which he also co-founded in 2013. He has commercial, project management and consulting experience through previous positions both in Ireland and the UK.

David Thurston is Professor of Drug Discovery in the Institute of Pharmaceutical Science at King’s College London. He has a first degree in pharmacy and a PhD in synthetic medicinal chemistry. David is one of the scientific co-founders of Spirogen Ltd (recently acquired by AstraZeneca), and acted as CSO for the company from its formation in 2000 until 2011. He is also a co-founder of Transcriptogen Ltd, which focusses on the discovery and development of small-molecule transcription factor inhibitors as oncology agents, and Femtogenix Ltd which is involved with the discovery of novel DNA Minor Groove Binding Agents (MGBAs) with potential application as ADC payloads. David has published widely in medicinal chemistry/chemistry journals, is author of the textbook “Chemistry and Pharmacology of Anticancer Drugs”, and Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry.

Paul Jackson holds an undergraduate degree in the pharmaceutical sciences (LJMU), an MSc in Bioinformatics (University of Liverpool) and a PhD in Computational Drug Discovery (King’s College London). He has extensive experience in in silico methods, including structure-, ligand- and fragment-based drug design. He has also been involved in the development of QSAR, lead optimization and molecular docking techniques. Both his PhD and post-doctoral research have involved the development of novel computational chemistry methods (e.g., molecular dynamics simulation techniques) for the design and evaluation of ADC payloads, which has contributed to Femtogenix’s novel payload discovery platform, a company of which he is scientific co-founder. Dr Jackson also provided the modelling support for the discovery of the novel NF-κB inhibitor TSG-1301 (KMR-28-39) which is presently in development with Transcriptogen Ltd, a company which he also co-founded in 2013. He has commercial, project management and consulting experience through previous positions both in Ireland and the UK.

David Thurston is Professor of Drug Discovery in the Institute of Pharmaceutical Science at King’s College London. He has a first degree in pharmacy and a PhD in synthetic medicinal chemistry. David is one of the scientific co-founders of Spirogen Ltd (recently acquired by AstraZeneca), and acted as CSO for the company from its formation in 2000 until 2011. He is also a co-founder of Transcriptogen Ltd, which focusses on the discovery and development of small-molecule transcription factor inhibitors as oncology agents, and Femtogenix Ltd which is involved with the discovery of novel DNA Minor Groove Binding Agents (MGBAs) with potential application as ADC payloads. David has published widely in medicinal chemistry/chemistry journals, is author of the textbook “Chemistry and Pharmacology of Anticancer Drugs”, and Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry.

Paul Jackson holds an undergraduate degree in the pharmaceutical sciences (LJMU), an MSc in Bioinformatics (University of Liverpool) and a PhD in Computational Drug Discovery (King’s College London). He has extensive experience in in silico methods, including structure-, ligand- and fragment-based drug design. He has also been involved in the development of QSAR, lead optimization and molecular docking techniques. Both his PhD and post-doctoral research have involved the development of novel computational chemistry methods (e.g., molecular dynamics simulation techniques) for the design and evaluation of ADC payloads, which has contributed to Femtogenix’s novel payload discovery platform, a company of which he is scientific co-founder. Dr Jackson also provided the modelling support for the discovery of the novel NF-κB inhibitor TSG-1301 (KMR-28-39) which is presently in development with Transcriptogen Ltd, a company which he also co-founded in 2013. He has commercial, project management and consulting experience through previous positions both in Ireland and the UK.

Paul Jackson holds an undergraduate degree in the pharmaceutical sciences (LJMU), an MSc in Bioinformatics (University of Liverpool) and a PhD in Computational Drug Discovery (King’s College London). He has extensive experience in in silico methods, including structure-, ligand- and fragment-based drug design. He has also been involved in the development of QSAR, lead optimization and molecular docking techniques. Both his PhD and post-doctoral research have involved the development of novel computational chemistry methods (e.g., molecular dynamics simulation techniques) for the design and evaluation of ADC payloads, which has contributed to Femtogenix’s novel payload discovery platform, a company of which he is scientific co-founder. Dr Jackson also provided the modelling support for the discovery of the novel NF-κB inhibitor TSG-1301 (KMR-28-39) which is presently in development with Transcriptogen Ltd, a company which he also co-founded in 2013. He has commercial, project management and consulting experience through previous positions both in Ireland and the UK.